J&J gets a boost from a possible covid-19 vaccine


In an intra date note to investors Gorilla Trades strategist Ken Berman, while commenting on Johnson & Johnson’s earnings and the production of a future COVID-19 vaccine, said:

Get Our Activist Investing Case Study!

Get the entire 10-part series on our in-depth study on activist investing in PDF. Save it to your desktop, read it on your tablet, or print it out to read anywhere! Sign up below!

Q1 2020 hedge fund letters, conferences and more

The major indices are all significantly higher at midday following a very active morning session on Wall Street. Yesterday’s trends continued in early trading, with the tech sector showing relative strength and cyclical issues lagging behind the broader market, despite the continued decline in the number of new COVID-cases in the U.S. More and more European countries are preparing to ease their lockdown rules as the number of new cases continues to drop in the previous epicenters of the pandemic as well, but bank stocks remained under pressure today, ‘infecting’ the U.S. financial sector too.

Jim O’Shaughnessy: Fear Signals Created By The Reptilian Brain

ValueWalk's Raul Panganiban interviews Jim O’Shaughnessy, Chairman, Co-chief Investment Officer, and Portfolio Manager at O’Shaughnessy Asset Management. In this part, Jim discusses the fear and emotional signals created by the reptilian brain. Q1 2020 hedge fund letters, conferences and more That's very cool. For the factor to try to seek the reason why it works, Read More

J&J Earnings And A Possible COVID-19 Vaccine Helps Boost The Stock

The earnings season kicked off today with JP Morgan (JPM, -4.4%) and Wells Fargo (WFC, -5.4%) reporting in pre-market trading. While both firms reported slightly better-than-expected numbers, their stocks are trading deep in the green due to mounting economic fears and the solvency issues in the most-affected sectors. Johnson & Johnson (JNJ, +4.9) surged to its highest level in six weeks in the wake of its report, as investors hailed the company’s better-than-expected earnings and its possible involvement in the production of a future COVID-19 vaccine.

Market Wrap

Market breadth was very strong just after the opening bell, but some of the key measures deteriorated later on, due to weakness among small caps, with advancing issues still outnumbering decliners by a 6-to-1 ratio on the NYSE. Only 3 stocks hit new 52-week lows on the NYSE and the Nasdaq, while 29 stocks hit new 52-week highs. The major indices dipped below their VWAPs (Volume-Weighted Average Price) following a positive start to the session, warning of a possible intraday reversal. Cyclical issues and small-caps have been weak this morning, and the financial sector’s troubles, in particular, warrant caution from a short-term perspective. Stay tuned!